Article
Oncology
Lucie Pehalova, Denisa Krejci, Jana Halamkova, Lenka Smardova, Lenka Snajdrova, Ladislav Dusek
Summary: The study found that the risk of subsequent hematological malignancies increased with the age-standardized incidence rate, and a significant change occurred in 1992. Individuals with a history of any cancer had a risk of hematological malignancies approximately 1.5 times higher than the general Czech population. Patients with myelodysplastic syndromes, polycythaemia vera, and non-Hodgkin lymphoma were at the highest risk of developing subsequent hematological malignancies.
CANCER EPIDEMIOLOGY
(2021)
Review
Anesthesiology
S. Fizza Haider, R. Sloss, S. Jhanji, E. Nicholson, B. Creagh-Brown
Summary: There are various haematological malignancies which may require critical care management. Identifying patients who will benefit from critical care admission is challenging and palliative care may be helpful in reducing non-beneficial treatments. This review offers an overview of relevant haematological malignancies for critical care physicians and discusses specific management strategies.
Review
Hematology
M. Veyri, J. P. Spano, F. Le Bras, A. G. Marcelin, E. Todesco
Summary: CD30 is a transmembrane protein expressed on a subset of activated T and B lymphocytes as well as lymphoid neoplasms. It is a promising therapeutic target due to its high levels in tumors and low levels in healthy tissues. Various therapeutic strategies have been developed, including monoclonal antibodies, bispecific antibodies, and cell and gene therapies such as anti-CD30 CAR-T cells. This review provides an overview of the biology of CD30 and describes the current anti-CD30 therapies.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Olivier J. Van Not, Alfons J. M. van den Eertwegh, John B. Haanen, Rozemarijn S. van Rijn, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Mick J. M. van Eijs, Jan-Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Melissa de Meza, Djura Piersma, Marion Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Karijn P. M. Suijkerbuijk, Willeke A. M. Blokx
Summary: Patients with haematologic malignancies have a higher risk of developing subsequent solid tumours, such as melanoma. Treatment with immune checkpoint inhibitors leads to worse outcomes in patients with haematologic malignancies compared to targeted therapy.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Cell Biology
Brian Krug, Ashot S. Harutyunyan, Shriya Deshmukh, Nada Jabado
Summary: This review discusses the deregulation of the epigenome in primary brain tumors in children and young adults, highlighting recurrent mutations, protein expression, and epigenetic alterations that promote oncogenicity. The review also emphasizes the narrow developmental windows permitting oncogenic potential and the potential reversibility of altered chromatin states.
TRENDS IN CELL BIOLOGY
(2021)
Review
Medicine, General & Internal
Manar Mosaad, Mohamed Hassan Elnaem, Ejaz Cheema, Ismail Ibrahim, Jamalludin Ab Rahman, Ahlam Naila Kori, How Soon Hin
Summary: This study discussed various risk assessment models across different malignancy types and their advantages and disadvantages. Different malignancy types correspond to different risk assessment scores, with some models performing well while others have limitations.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Oncology
Emma Willmott, Maria Loades, Laura Baker, Anna Spathis
Summary: Clinicians perceive CRF as a common but individual experience for TYAs, and face various challenges in assessing and managing CRF for this group, such as limited knowledge, difficulties engaging TYAs, and inadequate time for consultations.
EUROPEAN JOURNAL OF CANCER CARE
(2021)
Article
Hematology
Raul Cordoba, Toby A. Eyre, Heidi D. Klepin, Tanya M. Wildes, Valentin Goede
Summary: Haematological malignancies are a diverse group of diseases with increasing incidence with age, particularly reaching a peak at 75-99 years, but overall survival is low for older adults, especially with acute leukaemias. Understanding the heterogeneity in outcomes, treatment challenges, and management of frailty and comorbidities among older patients can help physicians better address the burden and mortality of haematological cancers in aging populations.
LANCET HAEMATOLOGY
(2021)
Article
Oncology
Nicola F. Hughes, Kirsten J. Cromie, Richard G. Feltbower, Martin G. Mccabe, Dan Stark
Summary: Adolescent and young adult (AYA) germ cell tumour (GCT) patients have lower survival rates, partially due to treatment factors. Research on cancer registration data and clinical trial datasets showed that higher relative dose intensity (RDI) is associated with improved survival outcomes. However, incomplete data poses limitations.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Kimberly J. Johnson, Xiaoyan Wang, Justin M. Barnes, Arash Delavar
Summary: The study shows that AYAs living in rural areas and farther from reporting hospitals are more likely to be diagnosed with late-stage cancer and have lower survival rates.
Article
Oncology
Gemma Pugh, Anika Petrella, Akshay Pabary, Aaron Cross, Rachael Hough, Louise Soanes, Catherine Sabiston, Abigail Fisher
Summary: The study reveals that TYA-HPs recognize the value and importance of promoting health behaviors but feel limited in their capability to provide advice. They suggest the need for cross-multidisciplinary team support for improved access to resources and skills-based training on delivering lifestyle advice.
Article
Oncology
Nina D. Arhin, Chan Shen, Christina E. Bailey, Lea K. Matsuoka, Alexander T. Hawkins, Andreana N. Holowatyj, Kristen K. Ciombor, Michael B. Hopkins, Timothy M. Geiger, Audrey E. Kam, Marc T. Roth, Cody M. Lebeck Lee, Michael Lapelusa, Arvind Dasari, Cathy Eng
Summary: The study showed that surgical resection of primary and/or metastatic sites in young-onset colorectal cancer patients significantly improves overall survival. Patients who underwent both primary tumor resection and metastasectomy had the greatest survival benefit compared to those who received palliative therapy.
Article
Pediatrics
Darren Klawinski, Issa Hanna, Nathaniel K. Breslin, Howard M. Katzenstein, Daniel J. Indelicato
Summary: Squamous cell carcinoma of the oral cavity is a common malignancy in the head and neck region, with risk factors including HPV infection, smoking, and alcohol use. HPV-positive SCC is more common in young adults, while HPV-negative disease is prevalent in older patients.
Article
Multidisciplinary Sciences
Elham Karimi, Miranda W. W. Yu, Sarah M. Maritan, Lucas J. M. Perus, Morteza Rezanejad, Mark Sorin, Matthew Dankner, Parvaneh Fallah, Samuel Dore, Dongmei Zuo, Benoit Fiset, Daan J. Kloosterman, LeeAnn Ramsay, Yuhong Wei, Stephanie Lam, Roa Alsajjan, Ian R. Watson, Gloria Roldan Urgoiti, Morag Park, Dieta Brandsma, Donna L. Senger, Jennifer A. A. Chan, Leila Akkari, Kevin Petrecca, Marie-Christine Guiot, Peter M. Siegel, Daniela F. Quail, Logan A. Walsh
Summary: Single-cell technologies have been used to study the tumour microenvironment and reveal cellular diversity in tumour cells and their surroundings. This study used imaging mass cytometry to analyze the immunological landscape of high-grade glioma and brain metastasis tumours. The analysis revealed differences in immune landscapes between primary tumours and brain metastases and identified a unique population of MPO-positive macrophages associated with long-term survival in glioblastoma patients. The findings highlight the importance of integrating spatial resolution into single-cell datasets to understand the microenvironment of cancer.
Article
Oncology
Marcela B. Mansur, Caroline L. Furness, Sirintra Nakjang, Amir Enshaei, Donat Alpar, Sue M. Colman, Lynne Minto, Julie Irving, Beth V. Poole, Elda P. Noronha, Suvi Savola, Sameena Iqbal, John Gribben, Maria S. Pombo-de-Oliveira, Tony M. Ford, Mel F. Greaves, Frederik W. van Delft
Summary: The study found that adolescent and young adult T-ALL does not have specific genetic abnormalities compared to pediatric or adult T-ALL, showing a transitional genomic profile.
Article
Oncology
L. Khoja, A. McGurk, C. O'Hara, S. Chow, J. Hasan
EUROPEAN JOURNAL OF CANCER
(2015)
Article
Oncology
C. O'Hara, A. Moran, J. S. Whelan, R. E. Hough, C. A. Stiller, M. C. G. Stevens, D. P. Stark, R. G. Feltbower, M. G. McCabe
EUROPEAN JOURNAL OF CANCER
(2015)
Article
Oncology
Nuradh Joseph, Cathy Taylor, Catherine O'Hara, Ananya Choudhury, Tony Elliott, John Logue, James Wylie
RADIOTHERAPY AND ONCOLOGY
(2016)
Article
Biochemistry & Molecular Biology
D. Gareth R. Evans, Catherine O'Hara, Anna Wilding, Sarah L. Ingham, Elizabeth Howard, John Dawson, Anthony Moran, Vilka Scott-Kitching, Felicity Holt, Susan M. Huson
EUROPEAN JOURNAL OF HUMAN GENETICS
(2011)
Correction
Biochemistry & Molecular Biology
D. Gareth R. Evans, Catherine O'Hara, Anna Wilding, Sarah L. Ingham, Elizabeth Howard, John Dawson, Anthony Moran, Vilka Scott-Kitching, Felicity Holt, Susan M. Huson
EUROPEAN JOURNAL OF HUMAN GENETICS
(2013)
Article
Oncology
A. Moran, C. O'Hara, S. Khan, L. Shack, E. Woodward, E. R. Maher, F. Lalloo, D. G. R. Evans
Article
Oncology
P. J. Barrow, S. Ingham, C. O'Hara, K. Green, I. McIntyre, F. Lalloo, J. Hill, D. G. Evans
Article
Genetics & Heredity
Sarah Louise Ingham, Jane Warwick, Iain Buchan, Sarah Sahin, Catherine O'Hara, Anthony Moran, Anthony Howell, D. Gareth Evans
JOURNAL OF MEDICAL GENETICS
(2013)
Article
Oncology
Emily A. J. Sehmer, G. J. Hall, David C. Greenberg, Catherine O'Hara, Sarah C. Wallingford, Karen A. Wright, Adele C. Green
Article
Oncology
Ramandeep S. Arora, Robert D. Alston, Tim O. B. Eden, Anthony Moran, Marco Geraci, Catherine O'Hara, Jillian M. Birch
PEDIATRIC BLOOD & CANCER
(2012)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)